MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctarc.2026.101430

Медицинская библиотека · Cancer treatment and research communications · 2026

Frailty, initial attrition and feasibility of novel platinum-free options for advanced non-small-cell lung cancer in the real-world setting.

Christopoulos Petros, Blasi Miriam, Langer Sandra, Shi Shuo, Cvetkovic Jelena, Bozorgmehr Farastuk, Allgäuer Michael, Yuskaeva Kadriya, Schneider Marc A, Shah Rajiv, Kuon Jonas, Stenzinger Albrecht, Glück Thomas, Thomas Michael

СтатьяПеревод в очереди

Аннотация

BACKGROUND

How frailty limits initial therapy in metastatic non-small-cell lung cancer (mNSCLC) remains poorly understood and was investigated in this study.

METHODS

We retrospectively analyzed 2592 consecutive patients with mNSCLC treated between 2018-2023.

RESULTS

Systemic therapy was initiated in 74% of patients with PD-L1 0-49% (n = 1306) vs. 79% with PD-L1 ≥50% (n = 507, p = 0.014), in whom availability of monoimmunotherapy reduced best supportive care (16.4%vs. 22.3%, p = 0.0002), while early death remained unchanged (ca. 4%). 70% of patients receiving mBSC were initially treatable but suffered early deterioration associated with comorbidities, metastatic burden, or protracted workup (p < 0.001). The atezolizumab Summary of Product Characteristics (SmPC) criteria, i.e. >80 years, or ECOG performance status (PS) ≥3, or comorbidities with PS ≥2 or age ≥70, were fulfilled by 38% (n = 501) and associated with 3-fold higher risk of death without therapy (230/501) compared to non-SmPC patients (p < 0.001). Under platinum, SmPC patients showed higher toxicity and shorter survival than non-SmPC patients, which for a platinum dose ratio ≤60% across 4 cycles (9% of 1306) resembled that with single-agent chemotherapy (median 5.1 months). SmPC criteria correlated with platinum use stronger than comorbidity scores, but predictability for individual patients remained modest (AUC 0.71, p < 0.001).

CONCLUSIONS

The high pretherapeutic attrition of 26% in mNSCLC improved with availability of monoimmunotherapy, but requires more efficient, faster patient workflows for further mitigation. Adoption of the SmPC criteria could support identification of patients at higher risk for mBSC or potential platinum overtreatment to enhance utilization of novel platinum-free first-line options.

Для цитирования: Christopoulos Petros, Blasi Miriam, Langer Sandra, Shi Shuo, Cvetkovic Jelena, Bozorgmehr Farastuk, Allgäuer Michael, Yuskaeva Kadriya, Schneider Marc A, Shah Rajiv, Kuon Jonas, Stenzinger Albrecht, Glück Thomas, Thomas Michael. Frailty, initial attrition and feasibility of novel platinum-free options for advanced non-small-cell lung cancer in the real-world setting.. Cancer treatment and research communications. 2026. DOI: 10.1016/j.ctarc.2026.101430.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.